\u2022\u00a0\u00a0 \u00a0Aquests resultats podrien tenir un impacte en el tractament dels pacients d\u2019aquestes dues malalties<\/p>\n
Investigadors de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i de la Universitat de Barcelona (UB) han descrit la capacitat d\u2019un inhibidor de la PI3K\u03b1 (BYL719) de bloquejar la formaci\u00f3 ect\u00f2pica d\u00b4os en ratolins, i que podria permetre millorar el tractament de dues patologies: la ossificaci\u00f3 heterot\u00f2pica i la fibrodispl\u00e0sia ossificant progressiva (FOP, una malaltia \u00f2ssia minorit\u00e0ria). L\u2019estudi ha estat liderat pel Dr. Francesc Ventura, cap del grup de Senyalitzaci\u00f3 Cel\u00b7lular i Biologia de l\u2019Os.<\/p>\n
\nL\u2019ossificaci\u00f3 heterot\u00f2pica (OH) consisteix en l\u2019aparici\u00f3 d\u2019ossificacions en llocs inapropiats (formaci\u00f3 ect\u00f2pica), com per exemple els tendons, m\u00fasculs i teixit connectiu. Per aquesta patologia existeixen factors de risc com la immobilitat perllongada, lesions de columna, cremades, operacions de maluc i traumes musculars. \u201cTot i saber aix\u00f2 encara no tenim un coneixement complet de les causes i el tractament m\u00e9s adequat per a la malaltia\u201d, comenta el Dr. Francesc Ventura.<\/p>\n
\nD\u2019altra banda, la FOP \u00e9s una malaltia minorit\u00e0ria, molt semblant a la OH per\u00f2 que t\u00e9 el seu origen en una mutaci\u00f3 gen\u00e8tica. Els pacients de FOP presenten mutacions en el gen que codifica per un receptor de factors de creixement ossi (BMPs), el ACVR1. La malaltia s\u00b4indueix paulatinament amb episodis d\u2019inflamaci\u00f3 que acaben resultant en la formaci\u00f3 progressiva d\u2019os en m\u00fasculs, tendons i lligaments. Aquestes ossificacions redueixen molt la mobilitat i l\u2019esperan\u00e7a de vida dels afectats. Actualment no hi ha tractament per aquesta malaltia.<\/p>\n
\n\u201cEl que hem observat en aquest estudi \u00e9s que, en c\u00e8l\u00b7lules mare en cultiu i en models precl\u00ednics de la malaltia, \u00a0l\u2019inhibidor BYL719 impedeix la formaci\u00f3 ect\u00f2pica d\u2019os indu\u00efda per les mutacions de ACVR1\u201d, explica el Dr. Ventura. L\u00b4inhibidor BYL719 va ser aprovat per la FDA el passat mes de maig per a la seva utilitzaci\u00f3 en pacients de c\u00e0ncer de mama metast\u00e0tic. Per tant, existeix una gran quantitat d\u2019informaci\u00f3 sobre l\u2019\u00fas de BYL719 en humans. \u201cEn aquest estudi hem demostrat que tamb\u00e9 pot tenir un paper important en la ossificaci\u00f3 i en el tractament d\u00b4aquestes malalties \u00f2ssies\u201d, afegeix Ventura.<\/p>\n","protected":false},"excerpt":{"rendered":"
L\u2019estudi descriu la capacitat d\u2019un inhibidor de la PI3-quinasa per combatre la Ossificaci\u00f3 Heterot\u00f2pica i la Fibrodispl\u00e0sia Ossificant Progressiva en models precl\u00ednics murins<\/p>\n","protected":false},"author":6,"featured_media":10458,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,338],"tags":[],"class_list":["post-7441","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-senyalitzacio-cellular-i-biologia-de-l-os"],"publishpress_future_action":{"enabled":false,"date":"2025-01-25 05:36:08","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7441"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7441\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10458"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}